Caribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest Update

Caribou Biosciences, Inc. (NASDAQ:CRBU) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 9,800,000 shares, an increase of 13.7% from the November 30th total of 8,620,000 shares. Approximately 12.4% of the company’s shares are sold short. Based on an average trading volume of 1,340,000 shares, the days-to-cover ratio is presently 7.3 days.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Erste Asset Management GmbH acquired a new stake in shares of Caribou Biosciences during the third quarter worth $28,000. AQR Capital Management LLC acquired a new stake in shares of Caribou Biosciences during the second quarter worth about $30,000. China Universal Asset Management Co. Ltd. boosted its position in Caribou Biosciences by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock valued at $34,000 after buying an additional 6,768 shares during the last quarter. Intech Investment Management LLC purchased a new position in Caribou Biosciences during the 3rd quarter worth approximately $43,000. Finally, Point72 DIFC Ltd lifted its stake in Caribou Biosciences by 389.4% during the 2nd quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock valued at $49,000 after acquiring an additional 23,995 shares during the period. 77.51% of the stock is owned by institutional investors and hedge funds.

Caribou Biosciences Price Performance

Shares of CRBU stock traded down $0.02 during mid-day trading on Wednesday, hitting $1.59. 1,714,111 shares of the stock traded hands, compared to its average volume of 1,690,717. The stock’s fifty day moving average is $2.04 and its two-hundred day moving average is $2.00. Caribou Biosciences has a 52-week low of $1.50 and a 52-week high of $8.33. The stock has a market cap of $143.98 million, a P/E ratio of -0.96 and a beta of 2.27.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The company had revenue of $2.02 million during the quarter, compared to the consensus estimate of $3.37 million. As a group, equities analysts forecast that Caribou Biosciences will post -1.64 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Caribou Biosciences in a report on Friday, November 15th. Citigroup dropped their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 26th. Four investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Caribou Biosciences currently has an average rating of “Buy” and a consensus target price of $10.20.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.